FibroBiologics Inc. said on Monday it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), allowing its common shares to continue trading on the Nasdaq Capital Market.
The clinical-stage biotechnology company, based in Houston, confirmed the development in a statement. Its shares, listed under ticker symbol FBLG, had previously fallen below the $1 threshold mandated by Nasdaq’s listing standards.
FibroBiologics, which focuses on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials, noted it remains compliant with all other Nasdaq listing requirements. The company holds more than 270 issued and pending patents, according to its profile.
The announcement follows the firm’s prior notification of non-compliance, which typically triggers a 180-day compliance period for companies to restore the minimum bid price. FibroBiologics did not disclose additional financial or operational details in the statement.
